Audentes Therapeutics (BOLD) Lifted to “Buy” at BidaskClub

Audentes Therapeutics (NASDAQ:BOLD) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

A number of other equities research analysts also recently weighed in on BOLD. Cowen restated a “buy” rating on shares of Audentes Therapeutics in a research report on Thursday, January 31st. Zacks Investment Research upgraded Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $28.00 target price for the company in a research report on Tuesday, January 8th. ValuEngine downgraded Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, November 12th. Mizuho restated a “buy” rating and issued a $45.00 target price on shares of Audentes Therapeutics in a research report on Friday, February 1st. Finally, William Blair reiterated a “hold” rating on shares of Audentes Therapeutics in a research report on Thursday, January 31st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the company. Audentes Therapeutics has an average rating of “Buy” and a consensus target price of $31.79.

BOLD opened at $26.27 on Friday. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of -7.73 and a beta of 1.79. Audentes Therapeutics has a 1-year low of $17.95 and a 1-year high of $46.18.

In other news, Director Louis G. Lange sold 32,000 shares of the stock in a transaction on Monday, December 24th. The stock was sold at an average price of $18.62, for a total transaction of $595,840.00. Following the completion of the sale, the director now owns 325,799 shares in the company, valued at approximately $6,066,377.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.60% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the company. NumerixS Investment Technologies Inc lifted its position in shares of Audentes Therapeutics by 1,200.0% during the 4th quarter. NumerixS Investment Technologies Inc now owns 1,300 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 1,200 shares during the last quarter. Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Audentes Therapeutics during the 4th quarter valued at $92,000. Great West Life Assurance Co. Can lifted its position in shares of Audentes Therapeutics by 96.0% during the 4th quarter. Great West Life Assurance Co. Can now owns 4,726 shares of the biotechnology company’s stock valued at $97,000 after acquiring an additional 2,315 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in shares of Audentes Therapeutics by 46.1% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,280 shares of the biotechnology company’s stock valued at $138,000 after acquiring an additional 1,983 shares during the last quarter. Finally, Legal & General Group Plc lifted its position in shares of Audentes Therapeutics by 34.5% during the 4th quarter. Legal & General Group Plc now owns 6,632 shares of the biotechnology company’s stock valued at $141,000 after acquiring an additional 1,700 shares during the last quarter. Institutional investors own 89.11% of the company’s stock.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Article: Lock-Up Period Expiration

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.